THE USE OF ZWITTERGENT-3-14 IN THE PURIFICATION OF RECOMBINANT HUMAN INTERFERON-BETA SER(L7) (BETASERON)

被引:25
作者
RUSSELLHARDE, D [1 ]
KNAUF, M [1 ]
CROZE, E [1 ]
机构
[1] BERLEX BIOSCI INC,DEPT PROT BIOCHEM & BIOPHYS,RICHMOND,CA 94804
关键词
D O I
10.1089/jir.1995.15.31
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
A new method for purifying human interferon-beta SER(17) from E, coli-derived inclusion bodies has been developed, This procedure eliminates the need for strong denaturants, such as sodium dodecyl sulfate or chaotropes, The procedure makes use of a nondenaturing detergent and a brief incubation at pH 12 to solubilize interferon-beta Se-17 from inclusion bodies, The detergent used was Zwittergent 3-14 (nonionic and pH-insensitive), which is included in the class of sulfobetaines (RN(+)(CH3)(2)(CH2)(x)SO3-). Zwittergent 3-14 was used in combination with urea to produce a urea/Zwittergent 3-14 washed inclusion body preparation enriched in human interferon-beta Se-17 (Betaseron). Solubilization of inclusion bodies was accomplished by employing a brief (1 minute) shift to pH 12 in the presence of 2.5% Zwittergent 3-14 followed by rapid adjustment to pH 8.0. Solubilization was complete, and the solution could be rapidly adjusted to pH 8 without any observable precipitation of protein, The resultant supernatant could be successfully subjected to a number of chromatographic and analytic procedures, many of which are not compatible with strong anionic detergents, such as SDS. Betaseron was purified from Zwittergent 3-14 solubilized inclusion body lysates using both ion-exchange and size-exclusion chromatography, Purified Betaseron retained bioactivity and could be refolded by simple dialysis against a nonreducing buffer, This method represents a novel procedure for purifying Betaseron from inclusion bodies using a nondenaturing detergent and ion-exchange chromatography.,
引用
收藏
页码:31 / 37
页数:7
相关论文
共 31 条
  • [21] PERDEW GH, 1983, ANAL BIOCHEM, V134, P453
  • [22] INTERFERONS AND THEIR ACTIONS
    PESTKA, S
    LANGER, JA
    ZOON, KC
    SAMUEL, CE
    [J]. ANNUAL REVIEW OF BIOCHEMISTRY, 1987, 56 : 727 - 777
  • [23] REDER AT, 1985, HDB CLIN NEUROLOGY, V3, P337
  • [24] Robinson A.B., 1974, CURR TOP CELL REGUL, V8, P248
  • [25] SHAKED Z, 1985, Patent No. 4530787
  • [27] LOCAL REACTIONS OF ZWITTERGENT-CONTAINING MENINGOCOCCAL VACCINE AFTER INTRAMUSCULAR INJECTION IN RATS - COMPARISON WITH THE EFFECT OF DIPHTHERIA PERTUSSIS TETANUS POLIO VACCINE
    SPEIJERS, GJA
    DANSE, LHJC
    BEUVERY, EC
    DERKS, HJGM
    VOS, JG
    [J]. VACCINE, 1988, 6 (05) : 419 - 422
  • [28] SUBACUTE TOXICITY OF ZWITTERGENT ADMINISTERED INTRAMUSCULARLY
    SPEIJERS, GJA
    DANSE, LHJC
    KRAJNCFRANKEN, MAM
    VANLEEUWEN, FXR
    HELLEMAN, PW
    BEUVERY, EC
    VOS, JG
    VANDERHEIJDEN, CA
    [J]. VACCINE, 1989, 7 (04) : 364 - 368
  • [29] SIZE AND DENSITY OF PROTEIN INCLUSION-BODIES
    TAYLOR, G
    HOARE, M
    GRAY, DR
    MARSTON, FAO
    [J]. BIO-TECHNOLOGY, 1986, 4 (06): : 553 - 557
  • [30] The IFNB Multiple Sclerosis Study Group, 1993, NEUROLOGY, V43, P655